AZ's gMG drug Klygefa nears EU approval
AstraZeneca's generalised myasthenia gravis (gMG) therapy Klygefa gets CHMP recommendation, alongside several other novel medicines.
Newsletters and Deep Dive digital magazine
AstraZeneca's generalised myasthenia gravis (gMG) therapy Klygefa gets CHMP recommendation, alongside several other novel medicines.
Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.
Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.
Novo has moved a step closer to EU approval of its long-acting haemophilia A therapy, Frehemgo, which could be a future blockbuster.
Editor's Picks
Newsletters and Deep Dive
digital magazine